Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140)

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 5, 1996, Pages 453-458

  Palomino, Eduardo ^a   Foster, Brenda ^b   Kempff, Maya ^c   Corbett, Thomas ^b   Wiegand, Richard ^b   Horwitz, Jerome ^b   Baker, Laurence ^b,d  

^a Walker Cancer Research Institute   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antitumor activity; Murine metabolism; PZA

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; ACRIDINE DERIVATIVE; DRUG METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; MALE; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; MALE; MASS SPECTROMETRY; MICE; NEOPLASMS, EXPERIMENTAL; OXIDATION-REDUCTION; PANCREATIC NEOPLASMS; PYRAZOLES; TUMOR CELLS, CULTURED;

EID: 0029762294     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050510     Document Type: Article

References (15)

1. Sebolt JS, Scavone SV, Pinter CD, Hamelehle KL, Von Hoff DD, Jackson RC (1987) Pyrazoloacridines, a new class of anticancer agents with selectivity against tumors in vitro. Cancer Res 47:4299
2. LoRusso P, Wozniak AJ, Polin L, Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME, Corbett TH (1990) Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res 50:4900
3. Jackson RC, Sebolt JS, Shillis JL, Leopold WR (1990) The Pyrazoloacridines: approaches to the development of a carcinoma selective cytotoxic agent. Cancer Invest 8:39
4. LoRusso PM, Foster BJ, Poplin E,Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker LH (1995) Phase I clinical trial of the pyrazoloacridine analog NSC 366140 (PD114934) Clin Cancer Res 1:1487
5. Denny WA, Atwell GJ, Anderson RF, Wilson WR (1990) Hypoxia selective antitumor agents. 4. Relationships between structure, physicochemical properties, and hypoxia-selective cytotoxicity for nitacrine analogueswith varying side chains: the "iminoacidan hypothesis". J Med Chem 33:1288
6. Berg SL, Balis FM, McCully CL, Godwin KS, Poplack DG (1991) Pharmacokinetics of pyrazoloacridine in the rhesus monkey. Cancer Res 51:5467
7. Foster BJ, Wiegand RA, LoRusso PM, Baker LH (1995) Pharmacokinetics of 9-methoxy- N.N-dimethyl-5-nitropyrazolo[3,4, 5-kl] acridine-2(6H) propanamine (PZA. PD 115934, NSC 366140) in mice. Clin Cancer Res 1:831
8. Rowinsky EK, Noe DA, Grochow LB, Sartorious SE, Bowling MK, Chen TL, Lubejko BG, Kaufmann SH, Donehower RC (1995) Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 13:1975
9. Donelli MG, Bartosek I, Guaitani A, Martini A, Colombo T, Paccianrini MA, Modica R (1976) Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect. Cancer Treat Rep 60:395
10. Gianni L, Vigano L, Surbone A, Ballinari D, Casali P, Tarello C, Collins JM, Bonnadonna G (1990) Pharmacology and clinical toxicity of 4′-iodo-4′-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst 82:469
11. Biernat L, Polin L, Corbett T (1992) Adaptation of mammary tumors of mice to a soft agar assay for use in drug discovery. Ann Oncology 3(1):105
12. Kedderis GL, Miwa GT (1988) The metabolic activation of nitroheterocyclic therapeutic agents. Drug Metab Rev 19:33
13. Saier MH (1987) Enzymes in metabolic pathways. Harper & Row, New York, p 68
14. Reid JM, Walker DL, Naylor S, Benson LM, Ames MM (1994) Murine metabolism of pyrazoloacridine (NSC-366140): identification and cytotoxicity of the urinary metabolites 9-desmethylpyrazoloacridine and pyrazoloacridine N-oxide. Proc Am Assoc Cancer Res 35:2512
15. Knox RJ, Friedlos F, Jarman M, Roberts JJ (1988) A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridinyl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol 37:4661